Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07224139 · ClinicalTrials.gov registry record
Sex-specific Risk Factors and Trajectories of Blood Biomarkers for Alzheimer's Disease and Related Dementias
A clinical trial of Alzheimer Disease and Dementia, sponsored by Anne Murray.
- Active
- Registry status
- 13,435
- Enrollment target
- 5
- Study locations
NCT07224139 is a study of Alzheimer Disease and Dementia that is active but no longer recruiting, run by Anne Murray. The registered enrollment target is 13,435 participants, above the 2,707-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (396% higher). The trial reports 5 study locations across 4 states.
The verdict
NCT07224139, a study of Alzheimer Disease and Dementia, is active but no longer recruiting, sponsored by Anne Murray.
- ACTIVE NOT RECRUITING
- Registry status
- 13,435 participants
- Enrollment target
- 5
- Study locations
Study Summary
Blood-based ADRD biomarkers show tremendous promise as a non-invasive method to predict and diagnose ADRD. We will measure changes in these biomarkers to determine whether their ability to predict ADRD differs by sex or by other characteristics, and develop a sex-specific ADRD risk score for personalized medicine and clinical trials.
Conditions Studied
Study Locations (5)
Minnesota
- Hennepin Healthcare Research Institute - Minneapolis
- Regents of the University of Minnesota - Advanced Research & Diagnostic - Minneapolis
Georgia
- Foundation for Atlanta Veterans Education and Research, Inc. - Decatur
North Carolina
- Wake Forest University - Winston-Salem
Victoria
- Monash University - Melbourne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13,435 participants |
| Start Date | 2022-07-01 |
| Est. Completion | 2027-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07224139
The ClinicalTrials.gov registry entry for NCT07224139 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 13,435 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 2,707-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (396% higher). The listed sponsor is Anne Murray, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 0 interventions.
NCT07224139 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Minnesota, Georgia, North Carolina.
Frequently Asked Questions
What is clinical trial NCT07224139 about?
NCT07224139 is a clinical study titled "Sex-specific Risk Factors and Trajectories of Blood Biomarkers for Alzheimer's Disease and Related Dementias". Blood-based ADRD biomarkers show tremendous promise as a non-invasive method to predict and diagnose ADRD. We will measure changes in these biomarkers to determine whether their ability to predict ADRD differs by sex or by other characteristics, and develop a sex-specific ADRD risk score for persona...
What is the current status of trial NCT07224139?
This trial is currently active not recruiting. The enrollment target is 13,435 participants. The study started on 2022-07-01. Estimated completion is 2027-08.
What conditions does trial NCT07224139 study?
This clinical trial studies the following conditions: Alzheimer Disease, Dementia, Cognitive Dysfunction.
Who is sponsoring clinical trial NCT07224139?
This trial is sponsored by Anne Murray, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07224139 being conducted?
This trial has 5 study locations across Georgia, Minnesota, North Carolina, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
RECRUITING · Phase 3
-
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
RECRUITING · Phase 4
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
RECRUITING · NA
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Cognitive Neurology Unit Clinical Registry
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.